On April 10, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported a brief update regarding mitazalimab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer. As part of these efforts, Alligator has signed a letter-of-intent with the French non-for-profit clinical cancer research organization Unicancer. Consequently, the parties are collaborating to establish the feasibility of, and prepare for, a global investigator sponsored Phase 3 study.

No development decisions have been taken at this time, and any such activities remain at an exploratory stage.

(Press release, Alligator Bioscience, APR 10, 2026, View Source [SID1234664296])